NCT00915057View on ClinicalTrials.gov

Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hepatitis, Viral, Human
Interventions
DRUG

NRL972

Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.

Trial Locations (4)

Unknown

MHAT Sveti Ivan Rilski EAD, Sofia

Clinical Institute Fundeni, Bucharest

Emergency Country Hospital Cluj, Cluj-Napoca

Private Clinic Algomed SRL, Timișoara

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY

NCT00915057 - Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972. | Biotech Hunter | Biotech Hunter